|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...1920212223242526272829...6566» |
- clindamycin phosphate / Generic mfg.
Enrollment closed: Clindamycin to Reduce Preterm Birth in a Low Resource Setting (clinicaltrials.gov) - Oct 8, 2015
P4, N=1726, Active, not recruiting, Sponsor: Christiana Care Health Services
Recruiting --> Active, not recruiting
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
New trial: Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=1, Not yet recruiting, Sponsor: GlaxoSmithKline
- Trial primary completion date: CARESS_PREMI: Contribution of Real Time Analyses of CARdio-RESpiratory Signals to the Diagnosis of Infection in PREterM Infants (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=500, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Nov 2017
- |||| amikacin inhalation solution (NKTR-061) / Nektar Therap
Trial primary completion date, Gram negative: Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia (clinicaltrials.gov) - Oct 6, 2015
P3, N=650, Recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2015 --> Nov 2017 Trial primary completion date: Jan 2016 --> Apr 2017
- Enrollment open: Scrub Typhus Pediatric Immunology Study (clinicaltrials.gov) - Oct 6, 2015
P=N/A, N=170, Recruiting, Sponsor: University of Oxford
Trial primary completion date: Jan 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- | Trial completion, Trial primary completion date: A Pilot Trial to Determine the Efficacy of Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA) (PROSE) (clinicaltrials.gov) - Oct 6, 2015
P2, N=49, Completed, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Sep 2011 --> Mar 2011
- oral live-attenuated Shigella sonnei vaccine (WRSs2) / National Institute of Allergy and Infectious Diseases
Trial completion: Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 (clinicaltrials.gov) - Oct 5, 2015
P1, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Sep 2011 --> Mar 2011 Recruiting --> Completed
- Enrollment open, Trial initiation date: CORAL: Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli (clinicaltrials.gov) - Oct 4, 2015
P=N/A, N=44, Recruiting, Sponsor: NIZO Food Research
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Sep 2015
- Enrollment change: Heterologous Effects of BCG in Healthy UK Adults (clinicaltrials.gov) - Oct 3, 2015
P=N/A, N=48, Recruiting, Sponsor: University of Oxford
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Sep 2015 N=40 --> 48
- Enrollment closed: Peristeen Bowel Irrigation System in Cauda Equina (clinicaltrials.gov) - Oct 2, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: University of Manitoba
N=40 --> 48 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: MVA(TB)029: Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (clinicaltrials.gov) - Oct 1, 2015
P2, N=248, Completed, Sponsor: Mark Hatherill
Recruiting --> Active, not recruiting Recruiting --> Completed | N=340 --> 248
- ||||| Shanchol (oral cholera vaccine) / Sanofi
Enrollment closed: A Study of Two Doses of Oral Cholera Vaccine (Shanchol (clinicaltrials.gov) - Sep 30, 2015
P3, N=336, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | N=340 --> 248 Recruiting --> Active, not recruiting
- ||||| ribaxamase (SYN-004) / Synthetic Biologics
New P2 trial: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI (clinicaltrials.gov) - Sep 29, 2015
P2, N=372, Not yet recruiting, Sponsor: Synthetic Biologics Inc.
- || aztreonam / Generic mfg.
Trial primary completion date: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=510, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Nov 2016
- Trial primary completion date, HEOR: Impact of Rapid Detection of MRSA (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=240, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2016 --> Nov 2016 Trial primary completion date: Jul 2015 --> Jul 2016
- ||| Trial completion, Enrollment change: Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT) (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=156, Completed, Sponsor: T2 Biosystems
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Completed | N=700 --> 156
- | vancomycin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial primary completion date: Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections (clinicaltrials.gov) - Sep 26, 2015
P3, N=252, Completed, Sponsor: Rabin Medical Center
Recruiting --> Completed | N=700 --> 156 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014
- || Trial primary completion date: TailoredT: Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=1200, Recruiting, Sponsor: MeMed Diagnostics Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014 Trial primary completion date: Dec 2015 --> Mar 2016
- meropenem / Generic mfg., colistin sulphate / Generic mfg.
Trial primary completion date: Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem (clinicaltrials.gov) - Sep 25, 2015
P4, N=360, Recruiting, Sponsor: Mical Paul
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Jun 2016 --> Nov 2016
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Sep 25, 2015
P3, N=177, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Jun 2016 --> Nov 2016 Active, not recruiting --> Completed
- vancomycin / Generic mfg.
Trial primary completion date: RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=200, Recruiting, Sponsor: Murdoch Childrens Research Institute
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- |||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Sep 25, 2015
P3, N=750, Recruiting, Sponsor: Novartis
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Aug 2016 --> Nov 2016
- ||| Altabax (retapamulin) / GSK, Almirall
Enrollment closed: Retapamulin for Reducing MRSA Nasal Carriage (clinicaltrials.gov) - Sep 25, 2015
P4, N=150, Active, not recruiting, Sponsor: University of California, Irvine
Trial primary completion date: Aug 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- ||| Altabax (retapamulin) / GSK, Almirall
Trial completion, Enrollment change: ALTARGOPMS: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=3612, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=3000 --> 3612
- New trial: Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=160, Recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New trial, IO biomarker, Pneumococcal vaccines: Pneumonia Vaccine in Aging HIV Positive Individuals (clinicaltrials.gov) - Sep 24, 2015
P0, N=51, Completed, Sponsor: University of Toledo Health Science Campus
- New trial: ScreenStaph: Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=160, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- Trial primary completion date: STAR-Too: Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (clinicaltrials.gov) - Sep 23, 2015
P2, N=80, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed | N=3000 --> 3612 Trial primary completion date: Oct 2015 --> Jul 2015
- ||| Enrollment open: Detection of Mycoplasma Pneumoniae (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=800, Recruiting, Sponsor: Meridian Bioscience, Inc.
Trial primary completion date: Oct 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- |||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) (clinicaltrials.gov) - Sep 22, 2015
P1/2, N=330, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| SQ-109 / Sequella
Trial completion: Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design (clinicaltrials.gov) - Sep 21, 2015
P2, N=365, Completed, Sponsor: Michael Hoelscher
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Sep 18, 2015
P2, N=43, Terminated, Sponsor: University of Florida
Active, not recruiting --> Completed N=480 --> 43 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Apr 2015; NIAID terminated the study due to low subject enrollment
- Enrollment open, IO biomarker: Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology (clinicaltrials.gov) - Sep 17, 2015
P1, N=50, Recruiting, Sponsor: University of Toronto
N=480 --> 43 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Apr 2015; NIAID terminated the study due to low subject enrollment Not yet recruiting --> Recruiting
- ||| New trial: Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- Enrollment closed, IO biomarker: Multi-Drug Resistant Tuberculosis in Korea (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=2040, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- Trial completion, Trial primary completion date: Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos (clinicaltrials.gov) - Sep 16, 2015
P1, N=60, Completed, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Completed --> Active, not recruiting Not yet recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2014
- |||| Trial completion, Enrollment change, Trial primary completion date: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65 (clinicaltrials.gov) - Sep 16, 2015
P2b, N=1044, Completed, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Not yet recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Completed | N=192 --> 1044 | Trial primary completion date: Jan 2016 --> Jul 2015
- |||| Trial completion: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (clinicaltrials.gov) - Sep 16, 2015
P2b, N=199, Completed, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recruiting --> Completed | N=192 --> 1044 | Trial primary completion date: Jan 2016 --> Jul 2015 Enrolling by invitation --> Completed
- levofloxacin / Generic mfg., tetracycline / Generic mfg., esomeprazole / Generic mfg.
New trial: Comparison of Two Rescue Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=160, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
- ||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P2 trial, Pneumococcal vaccines: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) (clinicaltrials.gov) - Sep 14, 2015
P2, N=690, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? (clinicaltrials.gov) - Sep 10, 2015
P3, N=60, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Enrolling by invitation --> Completed Recruiting --> Completed
- New trial: Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=101, Completed, Sponsor: Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Phase classification: Post Market Surveillance to Observe Safety of Prevenar13™ in Adults (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=600, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Phase classification: P4 --> P=N/A
- ||||| Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
Enrollment closed: A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants (clinicaltrials.gov) - Sep 8, 2015
P3, N=320, Active, not recruiting, Sponsor: GlaxoSmithKline
Phase classification: P4 --> P=N/A Recruiting --> Active, not recruiting
- New trial: Gastric and Duodenal Microbiota in Dyspeptic Subjects (clinicaltrials.gov) - Sep 8, 2015
P=N/A, N=200, Recruiting, Sponsor: Konkuk University Medical Center
- |||| gepotidacin (GSK2140944) / GSK
Trial completion, Enrollment change, Trial primary completion date, Gram positive: Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Sep 8, 2015
P2, N=126, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Completed | N=240 --> 126 | Trial primary completion date: Nov 2015 --> Jun 2015
- |||| Shanchol (oral cholera vaccine) / Sanofi
Trial completion: A Study of Two Doses of Oral Cholera Vaccine (Shanchol (clinicaltrials.gov) - Sep 8, 2015
P4, N=336, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | N=240 --> 126 | Trial primary completion date: Nov 2015 --> Jun 2015 Active, not recruiting --> Completed
- New trial: CORAL: Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=44, Not yet recruiting, Sponsor: NIZO Food Research
- | Dexilant (dexlansoprazole) / Takeda
New P4 trial: Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Sep 4, 2015
P4, N=177, Completed, Sponsor: Kaohsiung Medical University
- New trial: Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=330, Completed, Sponsor: Kaohsiung Veterans General Hospital.